
Although fortification of expressed breast milk (EBM) via commercially available human milk fortifiers (HMF) has been shown to increase short-term weight and length among preterm very low-birth-weight (VLMW) neonates, widespread adoption of HMF is hampered by high cost and the increased risk of severe adverse events.





























